Records Examined: SOP Number/ Revision/ Date	Relevant Aspect of Standards Method Reference Y N N/A Comm	Fa	cility Name:				V]	ELAP I	D		
Records Examined: SOP Number/ Revision/ Date	Records Examined: SOP Number/ Revision/ Date	As	ssessor Name:	Analyst Name:	Inspection Date						
Sample ID:	Sample ID:	Re	elevant Aspect of Standards			Υ	N	N/A	Comments		
1. Is the linear calibration range determined initially, and does it contain a minimum of a blank and three standards? 2. Is linearity reestablished if any verification data exceeds initial calibration values by ±10%? 3. Is a laboratory control sample analyzed with every batch, and is recovery assessed against current laboratory criteria? NOTE: The laboratory "should" establish upper and lower control limits from control charts based on % recovery. 4. Is at least one method blank carried through all the procedural steps with each batch? 5. Is the calibration verified using a calibration standard after every ten samples or every analytical batch? 6. Is a minimum of 10% of all samples spiked with the stock standard? 7. For compliance monitoring, is the concentration of the matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? Amethod Supplement 1, Rev. 2 (MS) 3.2.1 MS 3.4.1.1 MS 3.4.3, 3.4.3.4, 3.4.3.4, 3.4.3.4, 3.4.3.5.	1. Is the linear calibration range determined initially, and does it contain a minimum of a blank and three standards? 2. Is linearity reestablished if any verification data exceeds initial calibration values by ±10%? 3. Is a laboratory control sample analyzed with every batch, and is recovery assessed against current laboratory criteria? NOTE: The laboratory "should" establish upper and lower control limits from control charts based on % recovery. 4. Is at least one method blank carried through all the procedural steps with each batch? 5. Is the calibration verified using a calibration standard after every ten samples or every analytical batch? 6. Is a minimum of 10% of all samples spiked with the stock standard? 7. For compliance monitoring, is the concentration of the matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? Amethod Supplement 1, Rev. 2 (MS) 3.2.1 MS 3.2.1 MS 3.4.3, 3.4.3.4, 3.4.3.5 MS 3.4.3.5 MS 3.4.3.5 MS 3.4.3.5 MS 3.4.3.5	Re	ecords Examined: SOP Number/ Revi	sion/ Date				Ar	nalyst:		
does it contain a minimum of a blank and three standards? 2. Is linearity reestablished if any verification data exceeds initial calibration values by ±10%? 3. Is a laboratory control sample analyzed with every batch, and is recovery assessed against current laboratory criteria? NOTE: The laboratory "should" establish upper and lower control limits from control charts based on % recovery. 4. Is at least one method blank carried through all the procedural steps with each batch? 5. Is the calibration verified using a calibration standard after every ten samples or every analytical batch? 6. Is a minimum of 10% of all samples spiked with the stock standard? 7. For compliance monitoring, is the concentration of the matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? 1. Rev. 2 (MS) 3.2.1 MS 3.2.1 MS 3.4.3, 3.4.3.4, 3.4.3.5 MS 3.4.3.5 MS 3.4.3.3.1	does it contain a minimum of a blank and three standards? 2. Is linearity reestablished if any verification data exceeds initial calibration values by ±10%? 3. Is a laboratory control sample analyzed with every batch, and is recovery assessed against current laboratory criteria? NOTE: The laboratory "should" establish upper and lower control limits from control charts based on % recovery. 4. Is at least one method blank carried through all the procedural steps with each batch? 5. Is the calibration verified using a calibration standard after every ten samples or every analytical batch? 6. Is a minimum of 10% of all samples spiked with the stock standard? 7. For compliance monitoring, is the concentration of the matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? 1, Rev. 2 (MS) 3.2.1 MS 3.2.1 MS 3.4.3, 3.4.3.4, 3.4.3.5 MS 3.4.3.5 MS 3.4.3.5 MS 3.4.3.5 MS 3.4.1.1 MS 3.3.1.1.1	Sa	ample ID: Date	e of Sample Prepa	aration:		Da	te of A	nalysis:		
exceeds initial calibration values by ±10%? 3. Is a laboratory control sample analyzed with every batch, and is recovery assessed against current laboratory criteria? NOTE: The laboratory "should" establish upper and lower control limits from control charts based on % recovery. 4. Is at least one method blank carried through all the procedural steps with each batch? 5. Is the calibration verified using a calibration standard after every ten samples or every analytical batch? 6. Is a minimum of 10% of all samples spiked with the stock standard? 7. For compliance monitoring, is the concentration of the matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? IMS 3.4.3, 3.4.3, 3.4.3.4, 3.4.3.5 MS 3.4.3.5 MS 3.4.3.5 MS 3.3.1.1.1	exceeds initial calibration values by ±10%? 3. Is a laboratory control sample analyzed with every batch, and is recovery assessed against current laboratory criteria? NOTE: The laboratory "should" establish upper and lower control limits from control charts based on % recovery. 4. Is at least one method blank carried through all the procedural steps with each batch? 5. Is the calibration verified using a calibration standard after every ten samples or every analytical batch? 6. Is a minimum of 10% of all samples spiked with the stock standard? 7. For compliance monitoring, is the concentration of the matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? IMS 3.4.3, 3.4.3, 3.4.3.4, 3.4.3.5 MS 3.4.1.1 MS 3.3.1.1.1	1.	does it contain a minimum of a blank		1, Rev. 2 (MS)						
laboratory criteria? NOTE: The laboratory "should" establish upper and lower control limits from control charts based on % recovery. 4. Is at least one method blank carried through all the procedural steps with each batch? 5. Is the calibration verified using a calibration standard after every ten samples or every analytical batch? 6. Is a minimum of 10% of all samples spiked with the stock standard? 7. For compliance monitoring, is the concentration of the matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? AMS 3.4.3.5 MS 3.4.3.5 MS 3.4.3.5 MS 3.4.3.5	batch, and is recovery assessed against current laboratory criteria? NOTE: The laboratory "should" establish upper and lower control limits from control charts based on % recovery. 4. Is at least one method blank carried through all the procedural steps with each batch? 5. Is the calibration verified using a calibration standard after every ten samples or every analytical batch? 6. Is a minimum of 10% of all samples spiked with the stock standard? 7. For compliance monitoring, is the concentration of the matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? MS 3.4.3, 3.4.3, 3.4.3.4, 3.4.3.5 MS 3.4.1.1 MS 3.4.1.1 MS 3.3.1.1.1	2.			MS 3.2.1						
5. Is the calibration verified using a calibration standard after every ten samples or every analytical batch? 6. Is a minimum of 10% of all samples spiked with the stock standard? 7. For compliance monitoring, is the concentration of the matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? AMS 4.5 MS 3.3.1	procedural steps with each batch? 5. Is the calibration verified using a calibration standard after every ten samples or every analytical batch? 6. Is a minimum of 10% of all samples spiked with the stock standard? 7. For compliance monitoring, is the concentration of the matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? MS 3.3.1.1.1	3.	batch, and is recovery assessed agai laboratory criteria? NOTE: The laboratory criteria? NOTE: The laboratory control limit	nst current ratory "should"							
after every ten samples or every analytical batch? 6. Is a minimum of 10% of all samples spiked with the stock standard? 7. For compliance monitoring, is the concentration of the matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? AMS 3.3.1 MS 3.3.1.1.1	after every ten samples or every analytical batch? 6. Is a minimum of 10% of all samples spiked with the stock standard? 7. For compliance monitoring, is the concentration of the matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? AMS 3.3.1 MS 3.3.1.1.1	4.		hrough all the	MS 3.4.1.1						
stock standard? 7. For compliance monitoring, is the concentration of the matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? 2.1	stock standard? 7. For compliance monitoring, is the concentration of the matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? 2.1	5.			MS 4.5						
matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? 2.1	matrix spike at the regulatory limit OR 1 to 5 times higher than the background concentration of the sample? 8. Were absorbencies measured at 578 nm? MS 3.3.1.1.1	6.		piked with the	MS 3.3.1						
		7.	matrix spike at the regulatory limit OF higher than the background concentration	R 1 to 5 times	MS 3.3.1.1.1						
Notes/Comments:	Notes/Comments:	8.	Were absorbencies measured at 578	nm?	2.1						
	Notes comments.	No	tes/Comments:								

TOTAL CYANIDE IN DRINKING, SALINE AND SURFACE WATERS, AND DOMESTIC AND INDUSTRIAL WASTES SEAL AQ2 METHOD NO: EPA-130-A REVISION 3

Rel	evant Aspect of Standards	Method Reference	Υ	N	N/A	Comments		
Records Examined: SOP Number/ Revision/ Date Analyst:								
Sar	mple ID: Date of Sample Pre	eparation: Date of Analysis:						
9.	Were samples subjected to manual reflux- distillation according to EPA 335.2 or 335.4 prior to analysis by this method?	1.4						
10.	Were samples that tested positive for the presence of sulfides by lead acetate test paper treated with powdered cadmium carbonate until negative for the presence of sulfides and then filtered?	4.1						
11.	Were samples that tested positive for chlorine on KI Starch paper treated with ascorbic acid until negative for the presence of chlorine?	4.2						
12.	Was volumetric glassware Class A?	6.2						
13.	Was Chloramine-T reagent prepared fresh daily?	7.1						
14.	Was Pyridine Barbituric Acid solution discarded if red-orange precipitate was observed?	7.1						
15.	Were samples collected in glass or plastic bottles?	8.1						
16.	Were wastewater samples preserved with NaOH to pH >10 and a reducing agent added if oxidizer present?	40CFR136.3 Table 1I,						
17.	Were wastewater samples held at ≤6°C, and analyzed within 14 days?	40CFR136.3 Table 1I						
18.	For drinking water, were samples adjusted to a pH of 12, chilled to 4°C, and analyzed within 14 days?	8.3, 40CFR141.40(a)(5)(i)						
19.	For drinking water, were samples that tested positive for sulfides held for no longer than 24 hours?	8.3, 40CFR141.40(a)(5)(i)						
20.	Were samples and calibration standards matrix matched, that is, 0.25 N Sodium Hydroxide?	10.2						
21.	Was any distillate that exceeded the calibration range diluted with 0.25N NaOH and not DI water?	12.2						
Not	es/Comments:							